{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:40:34Z","timestamp":1721436034241},"posted":{"date-parts":[[2024,6,26]]},"group-title":"In Review","reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,6,4]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Purpose: <\/bold>To perform a molecular profiling of the metastases from papillary thyroid carcinomas (PTCs) and poorly differentiated thyroid carcinomas (PDTCs). \n<bold>Methods: <\/bold>We retrieved and analyzed the molecular and clinical features of 136 metastases from PTCs and 35 metastases from PDTCs subjected to targeted DNA sequencing, from cBioPortal. The clinicopathological data included the number and location of the metastases, and<bold> <\/bold>genomic data included mutations, translocations, copy number alterations and fraction of the genome altered (FGA). \n<bold>Results: <\/bold>Bone metastases from PTCs<bold> <\/bold>had a lower frequency of <italic>BRAF<\/italic> mutations than the lymph node metastases (LNMs) (43% vs 88%, p&lt;0.01), and a higher frequency of <italic>RBM10<\/italic> and <italic>NRAS<\/italic> mutations than the LNMs (21% vs 3% for both, p&lt;0.05). The FGA of the bone metastases was higher than the FGA of the lung metastases (5.6% vs 1.3%, p&lt;0.05). The frequency of <italic>RET<\/italic>translocations was higher in the lung metastases from PTCs than the LNMs (15% vs 3%, p&lt;0.05). The LNMs from PTC patients harboring 4 or more distant metastases (DMs) had a higher frequency of <italic>TERT<\/italic>promoter mutations than the LNMs from patients harboring less than 4 DMs (96% vs 65%, p&lt;0.001). <italic>SDHA<\/italic> gene amplifications were enriched in the bone metastases from PDTCs and absent in the LNMs (38% vs 0%, p&lt;0.05). <bold>Conclusion: <\/bold>Metastases from PTCs and PDTCs harbor clinically relevant alterations affecting distinct body locations, such as <italic>NRAS<\/italic> and <italic>RBM10<\/italic> mutations, <italic>RET<\/italic> translocations and <italic>SDHA<\/italic>amplifications that may be explored therapeutically.<\/p>","DOI":"10.21203\/rs.3.rs-4528308\/v1","type":"posted-content","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T15:11:56Z","timestamp":1719414716000},"source":"Crossref","is-referenced-by-count":0,"title":["Genomic profiling of lymph node and distant metastases from papillary and poorly differentiated thyroid carcinomas"],"prefix":"10.21203","author":[{"given":"Valdemar","family":"M\u00e1ximo","sequence":"first","affiliation":[{"name":"i3S \u2013 Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto"}]},{"given":"Miguel","family":"Melo","sequence":"additional","affiliation":[{"name":"i3S \u2013 Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto"}]},{"given":"Manuel","family":"Sobrinho-Sim\u00f5es","sequence":"additional","affiliation":[{"name":"IPATIMUP \u2013 Instituto de Patologia e Imunologia Molecular da Universidade do Porto"}]},{"given":"Paula","family":"Soares","sequence":"additional","affiliation":[{"name":"i3S \u2013 Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto"}]},{"given":"Arnaud Da Cruz","family":"Paula","sequence":"additional","affiliation":[{"name":"i3S \u2013 Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"1. P. Mishra, D. Laha, R. Grant & N. Nilubol. Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer. Cancers 13, 6194 (2021). https:\/\/doi.org\/10.3390\/cancers13246194","DOI":"10.3390\/cancers13246194"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"2. V. M\u00e1ximo, et al. Genomic profiling of primary and metastatic thyroid carcinomas. Endocr Relat Cancer 31, e230144 (2024). https:\/\/doi.org\/10.1530\/ERC-23-0144","DOI":"10.1530\/ERC-23-0144"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"3. Y. Fang, et al. Genetic and clinical profiles of 160 papillary thyroid cancers with lateral neck lymph node metastasis. Front Oncol 12, 1057532 (2023). https:\/\/doi.org\/10.3389\/fonc.2022.1057532","DOI":"10.3389\/fonc.2022.1057532"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"4. E. Song, et al. Genetic profile of advanced thyroid cancers in relation to distant metastasis. Endocr Relat Cancer 27, 285\u2013293 (2020). https:\/\/doi:10.1530\/ERC-19-0452","DOI":"10.1530\/ERC-19-0452"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. B. Nguyen, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563\u2013575 (2022). https:\/\/doi:10.1016\/j.cell.2022.01.003","DOI":"10.1016\/j.cell.2022.01.003"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6. A. Zehir, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23, 703\u2013713 (2017). https:\/\/doi:10.1038\/nm.4333","DOI":"10.1038\/nm.4333"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"7. A. Da Cruz Paula, et al. Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. Gynecol Oncol 161, 535\u2013544 (2021). https:\/\/doi:10.1016\/j.ygyno.2021.02.015","DOI":"10.1016\/j.ygyno.2021.02.015"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"8. S.H. Kim, et al. Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. Nat Commun 11, 44 (2020). https:\/\/doi:10.1038\/s41467-019-13806-x","DOI":"10.1038\/s41467-019-13806-x"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9. J.S. Bae, et al. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of BRAF V600E mutation. Diagn Pathol 11, 21 (2016). https:\/\/doi:10.1186\/s13000-016-0458-6","DOI":"10.1186\/s13000-016-0458-6"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. V. Sancisi, D. Nicoli, M. Ragazzi, S. Piana & A. Ciarrocchi. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 9, E1745-9 (2012). https:\/\/doi:10.1210\/c.2012-1526","DOI":"10.1210\/jc.2012-1526"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. F. Pani, et al. Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: a case report. Oncol Lett 2, 2186\u20132190 (2017). https:\/\/doi:10.3892\/ol.2017.6395","DOI":"10.3892\/ol.2017.6395"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"12. S. Kato, et al. Ret aberrations in diverse cancers: next-generation sequencing of 4,8171 patients. Clin Cancer Res 8, 1988\u20131997 (2017).","DOI":"10.1158\/1078-0432.CCR-16-1679"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13. R. Martins, T.L. Jesus, L. Cardoso, P. Soares, & J. Vinagre. Personalized medicine in medullary thyroid carcinoma: a broad review of emerging treatments. J Pers Med 7, 1132 (2023). https:\/\/doi:10.3390\/jpm13071132","DOI":"10.3390\/jpm13071132"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. M. Melo, et al. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. J Clin Endocrinol Metab 102, 1898\u20131907 (2017). https:\/\/doi:10.1210\/jc.2016-2785","DOI":"10.1210\/jc.2016-2785"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15. K. Pak, S. Suh, S.K. Kim & I.J. Kim. Prognostic value of genetic mutations in thyroid cancer: a meta-analysis. Thyroid 25, 63\u201370 (2014). https:\/\/doi:10.1089\/thy.2014.0241","DOI":"10.1089\/thy.2014.0241"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16. S.K. Yoo, et al. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nat Commun 10, 2764 (2019). https:\/\/doi:10.1038\/s41467-019-10680-5","DOI":"10.1038\/s41467-019-10680-5"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17. N. Pozdeyev, L.M. Gay, E.S. Sokol, et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res 13, 3059\u20133068 (2018). https:\/\/doi:10.1158\/1078-0432.CCR-18-0373","DOI":"10.1158\/1078-0432.CCR-18-0373"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"18. H. Chen, et al. Molecular profile of advanced thyroid carcinomas by next-generation sequencing: characterizing tumors beyond diagnosis for targeted therapy. Mol Cancer Ther 7, 1575\u20131584 (2018). https:\/\/doi:10.1158\/1535-7163.MCT-17-0871","DOI":"10.1158\/1535-7163.MCT-17-0871"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19. A.M. Praiss, et al. TERT promoter mutations and gene amplifications in endometrial cancer. Gynecol Oncol 179, 16\u201323 (2023). https:\/\/doi:10.1016\/j.ygyno.2023.10.007","DOI":"10.1016\/j.ygyno.2023.10.007"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20. L. Wang, et al. Exploiting metabolic vulnerabilities of ovarian cancer with upregulated succinate dehydrogenase. Cancer Res 83, 7 (2023)","DOI":"10.1158\/1538-7445.AM2023-6032"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4528308\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4528308\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:25:59Z","timestamp":1721435159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4528308\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":20,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4528308\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1007\/s12020-024-03968-0","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,6,26]]},"subtype":"preprint"}}